The mysterious pathways of cardiac myxomas: A review of histogenesis, pathogenesis and pathology

Histopathology

Volumn 66, Issue 3, 2015, Pages 321-332

  Di Vito, Anna ^a   Mignogna, Chiara ^a   Donato, Giuseppe ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Cardiac myxoma; Epithelial mesenchymal transition; Extracellular matrix; Periostin; Tenascin

Indexed keywords

EMBRYOLOGY; ENDOCARDIUM; FIBROBLAST; HEART MUSCLE; HEART MUSCLE FIBROBLAST; HEART MYXOMA; HISTOGENESIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; PATHOLOGY; PLASTICITY; PRIORITY JOURNAL; REVIEW; CELL TRANSFORMATION; HEART TUMOR; MYXOMA;

CELL TRANSFORMATION, NEOPLASTIC; HEART NEOPLASMS; HUMANS; MYXOMA;

EID: 84921448268     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12531     Document Type: Review

References (126)

1. Burke AP, Tazeelar H, Gomez-Roman JJ et al. Benign tumours of pluripotent mesenchyme. In Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC eds. World Health Organization tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004; 260-265.
2. Burke AP, Virmani R. Cardiac myxoma. A clinicopathologic study. Am. J. Clin. Pathol. 1993; 100; 671-680.
3. Riberi A, Gariboldi V, Grisoli D et al. Cardiac tumors. Rev. Pneumol. Clin. 2010; 66; 95-103.
4. Hutchins GM, Bulkley BH. Atrial myxomas: a fifty year review. Am. Heart J. 1979; 97; 639-643.
5. Carney JA, Gordon H, Carpenter PC et al. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Balt.) 1985; 64; 270-283.
6. Virmani R, Burke A, Farb A, Atkinson JB. Cardiovascular pathology. Philadelphia, PA: Saunders, 2001; 437.
7. Harris IS, Black BL. Development of the endocardium. Pediatr. Cardiol. 2010; 31; 391-399.
8. Prichard RW. Tumors of the heart - review of the subject and report of 150 cases. AMA Arch. Pathol. 1951; 51; 98-128.
9. Acebo E, Val-Bernal JF, Gomez-Roman JJ. Prichard's structures of the fossa ovalis are not histogenetically related to cardiac myxoma. Histopathology 2001; 39; 529-535.
10. Val-Bernal JF, Martino M, Mayorga M, Garijo MF. Prichard's structures of the fossa ovalis are age-related phenomena composed of nonreplicating endothelial cells: the cardiac equivalent of cutaneous senile angioma. APMIS 2007; 115; 1234-1240.
11. Dewald GW, Dahl RJ, Spurbeck JL et al. Chromosomally abnormal clones and nonrandom telomeric translocations in cardiac myxomas. Mayo Clin. Proc. 1987; 62; 558-567.
12. Yin Z, Kirschner LS. PRKAR1A plays an essential role in cardiac development and myxomagenesis. Trends Cardiovasc. Med. 2009; 19; 44-49.
13. Vazir A, Douthwaite H. Rapidly growing left atrial myxoma: a case report. J. Med. Case Rep. 2011; 5; 417-418.
14. Donato G, Conforti F, Zuccalà V et al. Expression of tenascin-c and CD44 receptors in cardiac myxomas. Cardiovasc. Pathol. 2009; 18; 173-177.
15. Streit A, Lee KJ, Woo I, Roberts C, Jessell TM, Stern CD. Chordin regulates primitive streak development and the stability of induced neural cells, but is not sufficient for neural induction in the chick embryo. Development 1998; 125; 507-519.
16. Huber TL, Zhou Y, Mead PE, Zon LI. Cooperative effects of growth factors involved in the induction of hematopoietic mesoderm. Blood 1998; 92; 4128-4137.
17. Marom K, Levy V, Pillemer G, Fainsod A. Temporal analysis of the early BMP functions identifies distinct anti-organizer and mesoderm patterning phases. Dev. Biol. 2005; 282; 442-454.
18. Nostro MC, Cheng X, Keller GM, Gadue P. Wnt, activin, and BMP signaling regulate distinct stages in the developmental pathway from embryonic stem cells to blood. Cell Stem Cell 2008; 2; 60-71.
19. Simões C, Peterkin T, Patient R. Fgf differentially controls cross-antagonism between cardiac and haemangioblast regulators. Development 2011; 138; 3235-3245.
20. Miquerol L, Kelly RG. Organogenesis of the vertebrate heart. Wiley Interdiscip. Rev. Dev. Biol. 2013; 2; 17-29.
21. Van Vliet P, Wu SM, Zaffran S, Pucéat M. Early cardiac development: a view from stem cells to embryos. Cardiovasc. Res. 2012; 96; 352-362.
22. Meilhac SM, Esner M, Kelly RG, Nicolas JF, Buckingham ME. The clonal origin of myocardial cells in different regions of the embryonic mouse heart. Dev. Cell 2004; 6; 685-698.
23. Cai L, Liang X, Shi Y et al. Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. Dev. Cell 2003; 5; 877-889.
24. Galli D, Domínguez JN, Zaffran S, Munk A, Brown NA, Buckingham ME. Atrial myocardium derives from the posterior region of the second heart field, which acquires left-right identity as Pitx2c is expressed. Development 2008; 135; 1157-1167.
25. Hoffmann D, Peterson MA, Friedland-Little JM, Anderson SA, Moskowitz IP. Sonic hedgehog is required in pulmonary endoderm for atrial septation. Development 2009; 136; 1761-1770.
26. Bondue A, Tännler S, Chiapparo G et al. Defining the earliest step of cardiovascular progenitor specification during embryonic stem cell differentiation. J. Cell Biol. 2011; 192; 751-765.
27. Männer J, Pérez-Pomares JM, Macías D, Muñoz-Chápuli R. The origin, formation and developmental significance of the epicardium: a review. Cells Tissues Organs 2001; 169; 89-103.
28. Wu M, Smith CL, Hall JA, Lee I, Luby-Phelps K, Tallquist MD. Epicardial spindle orientation controls cell entry into the myocardium. Dev. Cell 2010; 19; 114-125.
29. Pérez-Pomares JM, Carmona R, González-Iriarte M, Atencia G, Wessels A, Muñoz-Chápuli R. Origin of coronary endothelial cells from epicardial mesothelium in avian embryos. Int. J. Dev. Biol. 2002; 6; 1005-1013.
30. Ieda M, Tsuchihashi T, Ivey KN et al. Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. Dev. Cell 2009; 16; 233-244.
31. Saga Y, Kitajima S, Miyagawa-Tomita S. Mesp1 expression is the earliest sign of cardiovascular development. Trends Cardiovasc. Med. 2000; 10; 345-352.
32. Bondue A, Lapouge G, Paulissen C et al. Mesp1 acts as a master regulator of multipotent cardiovascular progenitor specification. Cell Stem Cell 2008; 3; 69-84.
33. Bondue A, Blanpain C. Mesp1: a key regulator of cardiovascular lineage commitment. Circ. Res. 2010; 107; 1414-1427.
34. Wei Y, Mikawa T. Fate diversity of primitive streak cells during heart field formation in ovo. Dev. Dyn. 2000; 219; 505-513.
35. Kattman SJ, Huber TL, Keller GM. Multipotent flk1 + cardiovascular progenitor cells give rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages. Dev. Cell 2006; 11; 723-732.
36. Moretti A, Caron L, Nakano A et al. Multipotent embryonic isl1 + progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell 2006; 127; 1151-1165.
37. Chen L, Fulcoli FG, Tang S, Baldini A. Tbx1 regulates proliferation and differentiation of multipotent heart progenitors. Circ. Res. 2009; 105; 842-851.
38. Misfeldt M, Boyle SC, Tompkins KL, Bautch VL, Labosky PA, Baldwin HS. Endocardial cells are a distinct endothelial lineage derived from Flk1 + multipotent cardiovascular progenitors. Dev. Biol. 2009; 333; 78-89.
39. Ema M, Faloon P, Zhang WJ et al. Combinatorial effects of Flk1 and Tal1 on vascular and hematopoietic development in the mouse. Genes Dev. 2003; 17; 380-393.
40. Wu M, Fujiwara Y, Cibulsky SM et al. Developmental origin of a bipotential myocardial and smooth muscle cell precursor in the mammalian heart. Cell 2006; 12; 1137-1150.
41. Yamashita J, Itoh H, Hirashima M et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature 2000; 408; 92-96.
42. Ferdous A, Caprioli A, Iacovino M et al. Nk2-5 transactivates the Ets-related protein 71 gene and specifies an endothelial/endocardial fate in the developing embryo. Proc. Natl Acad. Sci. USA 2009; 106; 814-819.
43. Milgrom-Hoffman M, Harrelson Z, Ferrara N, Zelzer E, Evans SM, Tzahor E. The heart endocardium is derived from vascular endothelial progenitors. Development 2011; 138; 4777-4787.
44. Drake J, Fleming PA. Vasculogenesis in the day 6.5 to 9.5 mouse embryo. Blood 2000; 95; 1671-1679.
45. Amano J, Kono T, Wada Y et al. Cardiac myxoma: its origin and tumor characteristics. Ann. Thorac. Cardiovasc. Surg. 2003; 9; 215-221.
46. Barh D, Kumar A, Chatterjee S, Liloglou T. Molecular features, markers, drug targets, and prospective targeted therapeutics in cardiac myxoma. Curr. Cancer Drug Targets 2009; 9; 705-716.
47. Ferrans VJ, Roberts WC. Structural features of cardiac myxomas. Histology, histochemistry, and electron microscopy. Hum. Pathol. 1973; 4; 111-146.
48. Fine G, Morales A, Horn RC Jr. Cardiac myxoma. A morphologic and histogenetic appraisal. Cancer 1968; 22; 1156-1162.
49. Kirschner LS, Kusewitt DF, Matyakhina L et al. A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res. 2005; 65; 4506-4514.
50. Lie JT. The identity and histogenesis of cardiac myxomas. A controversy put to rest. Arch. Pathol. Lab. Med. 1989; 113; 724-726.
51. Snarr S, Kern CB, Wessels A. Origin and fate of cardiac mesenchyme. Dev. Dyn. 2008; 237; 2804-2819.
52. Schroeder JA, Jackson LF, Lee DC, Camenisch TD. Form and function of developing heart valves: coordination by extracellular matrix and growth factor signaling. J. Mol. Med. (Berl.) 2003; 81; 392-403.
53. Singh R, Hoogaars WM, Barnett P et al. Tbx2 and Tbx3 induce atrioventricular myocardial development and endocardial cushion formation. Cell. Mol. Life Sci. 2012; 69; 1377-1389.
54. Song L, Fässler R, Mishina Y, Jiao K, Baldwin HS. Essential functions of Alk3 during AV cushion morphogenesis in mouse embryonic hearts. Dev. Biol. 2007; 301; 276-286.
55. Combs MD, Yutzey KE. Heart valve development: regulatory networks in development and disease. Circ. Res. 2009; 105; 408-421.
56. Rivera-Feliciano J, Lee KH, Kong SW et al. Development of heart valves requires Gata4 expression in endothelial-derived cells. Development 2006; 133; 3607-3618.
57. Lincoln J, Kist R, Scherer G, Yutzey KE. Sox9 is required for precursor cell expansion and extracellular matrix organization during mouse heart valve development. Dev. Biol. 2007; 305; 20-32.
58. Gitler AD, Epstein JA. Regulating heart development: the role of Nf1. Cell Cycle 2003; 2; 96-98.
59. Nanba D, Kinugasa Y, Morimoto C et al. Loss of HB-EGF in smooth muscle or endothelial cell lineages causes heart malformation. Biochem. Biophys. Res. Commun. 2006; 350; 315-321.
60. Jiao K, Langworthy M, Batts L, Brown CB, Moses HL, Baldwin HS. Tgfbeta signaling is required for atrioventricular cushion mesenchyme remodeling during in vivo cardiac development. Development 2006; 133; 4585-4593.
61. Lie-Venema H, van den Akker NM, Bax NA et al. Origin, fate, and function of epicardium-derived cells (EPDCs) in normal and abnormal cardiac development. ScientificWorldJournal 2007; 7; 1777-1798.
62. Zhou B, Ma Q, Rajagopal S. Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature 2008; 454; 109-113.
63. de Lange FJ, Moorman AF, Anderson RH et al. Lineage and morphogenetic analysis of the cardiac valves. Circ. Res. 2004; 95; 645-654.
64. Perez-Pomares JM, Phelps A, Sedmerova M et al. Experimental studies on the spatiotemporal expression of WT1 and RALDH2 in the embryonic avian heart: a model for the regulation of myocardial and valvuloseptal development by epicardially derived cells (EPDCs). Dev. Biol. 2002; 247; 307-326.
65. Moorman AF, Christoffels VM. Cardiac chamber formation: development, genes, and evolution. Physiol. Rev. 2003; 83; 1223-1267.
66. Cossu G, Bianco P. Mesoangioblasts - vascular progenitors for extravascular mesodermal tissues. Curr. Opin. Genet. Dev. 2003; 13; 537-542.
67. Norris RA, Borg TK, Butcher JT, Baudino TA, Banerjee I, Markwald RR. Neonatal and adult cardiovascular pathophysiological remodeling and repair: developmental role of periostin. Ann. NY Acad. Sci. 2008; 1123; 30-40.
68. Souders CA, Bowers SL, Baudino TA. Cardiac fibroblast: the renaissance cell. Circ. Res. 2009; 105; 1164-1176.
69. Orlandini M, Oliviero S. In fibroblasts Vegf-D expression is induced by cell-cell contact mediated by cadherin-11. J. Biol. Chem. 2001; 276; 6576-6581.
70. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu. Rev. Pharmacol. Toxicol. 2005; 45; 657-687.
71. Corda S, Samuel JL, Rappaport L. Extracellular matrix and growth factors during heart growth. Heart Fail. Rev. 2000; 5; 119-130.
72. Lindsey ML, Escobar GP, Mukherjee R et al. Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation 2006; 113; 2919-2928.
73. Murakami M, Simons M. Fibroblast growth factor regulation of neovascularisation. Curr. Opin. Hematol. 2008; 15; 215-220.
74. Orlandi A, Ciucci A, Ferlosio A et al. Increased expression and activity of matrix metalloproteinases characterize embolic cardiac myxomas. Am. J. Pathol. 2006; 166; 1619-1628.
75. Kovacic JC, Mercader N, Torres M, Boehm M, Fuster V. Epithelial-to-mesenchymal and endothelial-to-mesenchymal transition: from cardiovascular development to disease. Circulation 2012; 125; 1795-1808.
76. Kirschner LS, Sandrini F, Monbo J, Lin JP, Carney JA, Stratakis CA. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex. Hum. Mol. Genet. 2000; 9; 3037-3046.
77. Salpea P, Horvath A, London E et al. Deletions of the PRKAR1A locus at 17q24.2-q24.3 in Carney complex: genotype-phenotype correlations and implications for genetic testing. J. Clin. Endocrinol. Metab. 2014; 99; E183-E188.
78. Horvath A, Bertherat J, Groussin L et al. Mutations and polymorphisms in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A): an update. Hum. Mutat. 2010; 31; 369-379.
79. Kirschner LS. PRKAR1A and the evolution of pituitary tumors. Mol. Cell. Endocrinol. 2010; 326; 3-7.
80. Veugelers M, Bressan M, McDermott DA et al. Mutation of perinatal myosin heavy chain associated with a Carney complex variant. N. Engl. J. Med. 2004; 351; 460-469.
81. Toydemir RM, Chen H, Proud VK et al. Trismus-pseudocamptodactyly syndrome is caused by recurrent mutation of MYH8. Am. J. Med. Genet. A 2006; 140; 2387-2393.
82. Yoshikai M, Kamohara K, Fumoto H, Kawasaki H. Left ventricular myxoma originating from the papillary muscle. J. Heart Valve Dis. 2003; 12; 177-179.
83. Rao RV, Walsh S, Chan V et al. Unusual cause of an ejection murmur: myxoma in the left ventricular outflow tract. Can. J. Cardiol. 2013; 29; 1742.e13-1742.e15.
84. Seethala S. Left ventricular myxoma: missed vs metastatic. World J. Cardiol. 2013; 5; 387-390.
85. Oliveira RG, Branco L, Dias L et al. Mitral valve myxomas: an unusual entity. Eur. J. Echocardiogr. 2008; 9; 181-183.
86. Choi CH, Park CH, Kim JS et al. Giant biatrial myxomanearly obstructing the orifice of the inferior vena cava. J. Cardiothorac. Surg. 2013; 8; 148-150.
87. Thiene G, Basso C, Rizzo S, Gerosa G, Stellin G, Valente M. Cardiac tumors: classification and epidemiology. In Basso C, Valente ML, Thiene G eds. Cardiac tumor pathology, current clinical pathology. New York: Springer Science and Business Media, 2013; 23-30.
88. Wold LE, Lie JT. Cardiac myxomas, a clinicopathological profile. Am. J. Pathol. 1980; 101; 219-230.
89. Aldridge HE, Greenwood WF. Myxoma of the left atrium. Br. Heart J. 1960; 22; 189-200.
90. Mouine NN, Asfalou II, Raissouni MM, Benyass AA, Zbir EM. Giant left atrial myxoma mimicking severe mitral valve stenosis and severe pulmonary hypertension. Int. Arch. Med. 2013; 6; 13-15.
91. Rohani A, Akbari V. A colossal atrial myxoma. J. Cardiovasc. Dis. Res. 2010; 1; 158-1600.
92. Alvarez JR, de Alegria AM, Quiroga JS et al. Rapid growth of left atrial myxoma after radiofrequency ablation. Tex. Heart Inst. J. 2013; 40; 459-461.
93. Park KJ, Woo JS, Park JY. Left atrial myxoma presenting with unusual cystic form. Korean J. Thorac. Cardiovasc. Surg. 2013; 46; 362-364.
94. Acikel S, Aksoy MM, Kilic H et al. Cystic and hemorrhagic giant left atrial myxoma in a patient presenting with exertional angina and dyspnea. Cardiovasc. Pathol. 2012; 21; e15-e18.
95. Krikler DM, Rode J, Davies MJ, Woolf N, Moss E. Atrial myxoma: a tumour in search of its origins. Br. Heart J. 1992; 67; 89-91.
96. Badrisyah I, Saiful R, Rahmat H, Naik VR, Tan YC. Brain metastasis of atrial myxoma: case report. Med. J. Malaysia 2012; 67; 613-615.
97. Walter JC, Walski-Easton SM, Nussbaum ES. Multiple intracranial aneurysms as delayed complications of an atrial myxoma: case report. Neurosurgery 2001; 49; 200-203.
98. Seo SM, Park SK, Kim SJ et al. Multiregional embolizations and Takotsubo cardiomyopathy associated with left atrial myxoma. Ann. Thorac. Cardiovasc. Surg. 2012; 18; 577-581.
99. Shin W, Choe YH, Kim SM, Song IY, Kim SS. Detection of cardiac myxomas with non-contrast chest CT. Acta Radiol. 2013; 55; 273-278.
100. Singh SK, Kumar A, Tewarson V et al. Calcified left atrial myxoma with osseous metaplasia. Indian J. Chest Dis. Allied Sci. 2012; 54; 201-203.
101. Panagiotou M, Panagopoulos ND, Ravazoula P et al. Large asymptomatic left atrial myxoma with ossification: case report. J. Cardiothorac. Surg. 2008; 3; 19-21.
102. Shapiro LM. Cardiac tumours diagnosis and management. Heart 2001; 85; 218-222.
103. Mendoza CE, Rosado MF, Bernal L. The role of interleukin-6 in cases of cardiac myxoma. Clinical features, immunologic abnormalities, and a possible role in recurrence. Tex. Heart Inst. J. 2001; 28; 3-77.
104. Lin JN, Lai CH, Lu LF, Lin HH. Fever of unknown origin from a left atrial myxoma: an immunological basis and cytokine association. South. Med. J. 2011; 104; 360-362.
105. Li Y, Pan Z, Ji Y et al. Herpes Simplex Virus Type 1 Infection associated with atrial myxoma. Am. J. Pathol. 2003; 163; 2407-2412.
106. Pateras IS, Evangelou K, Tsimaratou K et al. Detection of herplex simplex virus-1 and -2 in cardiac myxomas. J. Biomed. Biotechnol. 2012; 2012; 823949.
107. Schurra UP, Berdajsb DA, Bodec B et al. No association between herpes simplex virus 1 and cardiac myxoma. Swiss Med. Wkly. 2011; 141; w13223.
108. Yoshioka D, Takahashi T, Ishizaka T, Higuchi T. Successful surgical resection of infected left atrial myxoma in a case complicated with disseminated intravascular coagulation and multiple cerebral infarctions: case report. J. Cardiothorac. Surg. 2011; 6; 68-71.
109. Chow WH, Chow L, Cheung KL et al. Infected atrial myxoma. Postgrad. Med. J. 1989; 65; 671-673.
110. Carney JA. Differences between nonfamilial and familial cardiac myxoma. Am. J. Surg. Pathol. 1985; 9; 53-55.
111. Cao H, Wu Y, Zhu J, Chen Y. Familial cardiac myxoma with multifocal recurrences: a case report and review of the literature. J. Biomed. Res. 2011; 25; 368-372.
112. Kudo A. Periostin in fibrillogenesis for tissue regeneration: periostin actions inside and outside the cell. Cell. Mol. Life Sci. 2011; 68; 3201-3207.
113. Donato G, Conforti F, Camastra C et al. The role of mast cells tryptase in cardiac myxoma: histogenesis and development of a challenging tumour. Oncol. Lett. 2014; 8; 379-383.
114. White RW, Hirst NA, Edward S et al. Plasmacytoid lymphoma within a left atrial myxoma: a rare coincidental dual pathology. Interact. Cardiovasc. Thorac. Surg. 2010; 10; 140-141.
115. Svec A, Rangaiah M, Giles M et al. EBV+ diffuse large B-cell lymphoma arising within atrial myxoma. An example of a distinct primary cardiac EBV+ DLBCL of immunocompetent patients. Pathol. Res. Pract. 2012; 208; 172-176.
116. Giorlandino A, Berretta M, Mignosa C et al. Incidental Epstein-Barr virus associated atypical lymphoid proliferation arising in a left atrial myxoma: a case of long survival without any postsurgical treatment and review of the literature. Cardiovasc. Pathol. 2013; 22; e5-e10.
117. Sakamoto H, Sakamaki T, Kanda T et al. Vascular endothelial growth factor is an autocrine growth factor for cardiac myxoma cells. Circ. J. 2004; 68; 488-493.
118. Acebo E, Val-Bernal JF, Gomez-Roman JJ. Thrombomodulin, calretinin and c-kit (CD117) expression in cardiac myxoma. Histol. Histopathol. 2001; 16; 1031-1036.
119. Tanimura A, Kitazono M, Nagayama K et al. Cardiac myxoma: morphologic, histochemical, and tissue culture studies. Hum. Pathol. 1988; 19; 316-322.
120. Rickelt S, Rizzo S, Doerflinger Y et al. A novel kind of tumor type-characteristic junction: plakophilin-2 as a major protein of adherens junctions in cardiac myxomata. Mod. Pathol. 2010; 23; 1429-1437.
121. Blum W, Schwaller B. Calretinin is essential for mesothelioma cell growth/survival in vitro: a potential new target for malignant mesothelioma therapy? Int. J. Cancer 2013; 133; 2077-2088.
122. Burke AP, Virmani R. Tumors of the heart and great vessels. In Atlas of tumor pathology, 3rd series, Fascicle 13. Washington, DC: Armed Forces Institute of Pathology, 1996.
123. Pucci A, Bartoloni G, Tessitore E et al. Cytokeratin profile and neuroendocrine cells in the glandular component of cardiac myxoma. Virchows Arch. 2003; 443; 618-624.
124. Zhang M, Ding L, Liu Y, Xue L. Cardiac myxoma with glandular elements: a clinicopathological and immunohistochemical study of five new cases with an emphasis on differential diagnosis. Pathol. Res. Pract. 2014; 210; 55-58.
125. Berger MD, Schneider J, Ballmer PE et al. Mucin-producing adenocarcinoma arising in an atrial myxoma. Ann. Diagn. Pathol. 2013; 17; 104-107.
126. Lin YS, Jung SM, Wu HH et al. Survivin expression in cardiac myxoma. Chang Gung Med. J. 2011; 34; 360-365.